Cite
HARVARD Citation
Alsina, M. et al. (n.d.). 664PPhase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). Annals of oncology. p. . [Online].